Masahiro Tsuboi reports on key results from ESMO Virtual Congress 2020 on LBA1: Osimertinib adjuvant therapy in patients (pts) with early stage EGFR mutated (EGFRm) NSCLC after tumour resection (ADAURA): sites of disease recurrence
Produced by ESMO, https://oncologypro.esmo.org
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.